Bortezomib for multiple myeloma
- 29 June 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 7 (10), 1337-1346
- https://doi.org/10.1517/14656566.7.10.1337
Abstract
The ubquitin-proteasome pathway is a key regulator of homeostasis within cells, degrading misfolded or redundant proteins, and also those involved in mediating transcription, cell-cycle progression and apoptosis. Inhibition of the 26S proteasome results in accumulation of such proteins and ultimately leads to cell death. Malignant cells are more susceptible to proteasome inhibition due to their higher proliferation rates, protein production and their dependence on anti-apoptotic molecules for cell survival. Bortezomib has recently gained European Commission approval for the treatment of relapsed multiple myeloma on the basis of clinical trials demonstrating its efficacy, tolerability and superiority to high-dose dexamethasone. Preclinical data demonstrates the ability to synergise with other chemotherapeutic agents and overcome drug resistance, and hence combination studies are underway. This review describes the pharmacology, toxicity, preclinical and clinical activity of bortezomib, predominantly in the setting of multiple myeloma.Keywords
This publication has 56 references indexed in Scilit:
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- Guidelines on the diagnosis and management of multiple myeloma 2005British Journal of Haematology, 2006
- Identification and Validation of Novel Therapeutic Targets for Multiple MyelomaJournal of Clinical Oncology, 2005
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- The HOX-MEIS connection in AMLBlood, 2005
- A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UKBritish Journal of Haematology, 2004
- The development of proteasome inhibitors as anticancer drugsCancer Cell, 2004
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- Thalidomide in multiple myeloma: current status and future prospectsBritish Journal of Haematology, 2002
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002